Evidence supporting early nutritional support with parenteral amino acid infusion

Area of Science:

• Neonatalogy
• Pediatric Nutrition
• Intensive Care Medicine

Background:

• Extremely low birth weight (ELBW) infants exhibit poor postnatal growth compared to in utero growth rates.
• Early protein deficiencies are a significant factor contributing to suboptimal growth outcomes in ELBW infants.
• ELBW infants receiving only glucose lose 1-2% of their body protein daily, highlighting the need for nutritional support.

Purpose of the Study:

• To evaluate the impact of early intravenous amino acid administration on protein balance and accretion in ELBW infants.
• To determine optimal amino acid dosages for improving protein status in premature neonates.
• To assess the short-term safety and efficacy of early amino acid provision.

Main Methods:

• Review of metabolic studies, observational data, and randomized clinical trials on early amino acid administration in premature infants.
• Analysis of protein balance and accretion rates at different intravenous amino acid intakes (1 g/kg/day vs. 3 g/kg/day).
• Evaluation of existing evidence regarding short-term outcomes of amino acid therapy.

Main Results:

• Intravenous amino acids improve protein balance and accretion in sick premature infants, even with low caloric intake.
• A dosage of 3 g/kg/day of amino acids achieves significant protein accretion, while 1 g/kg/day results in near-zero balance.
• Short-term safety and efficacy of early amino acid administration are well-supported by current evidence.

Conclusions:

• Providing 2.5 to 3.5 g/kg/day of intravenous amino acids as early as possible is a reasonable recommendation for ELBW infants.
• Further research is needed to ascertain if higher amino acid doses (3-3.5 g/kg/day) optimize long-term growth and neurodevelopmental outcomes.
• Early nutritional intervention with amino acids is critical for mitigating protein loss and supporting growth in extremely premature neonates.